Torrent Pharma Inc

CLOSEOUT LETTER Torrent Pharma Inc MARCS-CMS 584701 — March 11, 2022 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: Return Receipt Requested Product: Drugs Recipient: Recipient Name Mr. Sanjay Gupta Recipient Title President and CEO Torrent Pharma Inc 2091 Hartel Ave. Levittown , PA 19057 United States sanjayqupta@torrentpharma.us Issuing Office: Division of Pharmaceutical Quality Operations I United States Dear Mr. Gupta: The Food and Drug Administration has completed evaluation of Torrent Pharma, Inc. corrective actions in response to our Warning Letter [WL #584701, dated October 28, 2019]. Based on our evaluation, it appears that you have addressed the violation(s) contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections. This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means. Sincerely, /S/ Craig Swanson Acting Program Division Director/District Director Office of Pharmaceutical Quality Operations Division I Content current as of: 03/18/2022 Regulated Product(s) Drugs